Published in J Clin Oncol on April 01, 1997
Results of the Dana-Farber Cancer Institute ALL Consortium Protocol 95-01 for children with acute lymphoblastic leukemia. Blood (2006) 2.62
Cardiotoxicity of anticancer treatments. Nat Rev Cardiol (2015) 2.28
Cardiotoxicity of anthracycline agents for the treatment of cancer: systematic review and meta-analysis of randomised controlled trials. BMC Cancer (2010) 2.25
Cardiotoxicity of anticancer treatments: what the cardiologist needs to know. Nat Rev Cardiol (2010) 1.80
Cardiotoxicity of doxorubicin is mediated through mitochondrial iron accumulation. J Clin Invest (2014) 1.77
Doxorubicin pathways: pharmacodynamics and adverse effects. Pharmacogenet Genomics (2011) 1.53
Anthracycline cardiotoxicity: prevalence, pathogenesis and treatment. Curr Cardiol Rev (2011) 1.50
Oxidative stress, redox signaling, and metal chelation in anthracycline cardiotoxicity and pharmacological cardioprotection. Antioxid Redox Signal (2012) 1.37
Human induced pluripotent stem cell-derived cardiomyocytes recapitulate the predilection of breast cancer patients to doxorubicin-induced cardiotoxicity. Nat Med (2016) 1.32
Phase II trial of trastuzumab in combination with cytotoxic chemotherapy for treatment of metastatic osteosarcoma with human epidermal growth factor receptor 2 overexpression: a report from the children's oncology group. J Clin Oncol (2012) 1.27
Senior adult oncology. J Natl Compr Canc Netw (2012) 1.20
Dexrazoxane and the ASCO guidelines for the use of chemotherapy and radiotherapy protectants: a critique. J Clin Oncol (2000) 1.13
The low incidence of secondary acute myelogenous leukaemia in children and adolescents treated with dexrazoxane for acute lymphoblastic leukaemia: a report from the Dana-Farber Cancer Institute ALL Consortium. Eur J Cancer (2011) 1.10
The current and future role of dexrazoxane as a cardioprotectant in anthracycline treatment: expert panel review. J Cancer Res Clin Oncol (2003) 1.03
Dexrazoxane prevents doxorubicin-induced long-term cardiotoxicity and protects myocardial mitochondria from genetic and functional lesions in rats. Br J Pharmacol (2007) 1.02
Both aerobic exercise and resveratrol supplementation attenuate doxorubicin-induced cardiac injury in mice. Am J Physiol Endocrinol Metab (2013) 1.01
Chemotherapy-Induced Cardiotoxicity: Overview of the Roles of Oxidative Stress. Oxid Med Cell Longev (2015) 0.95
N-acetylcysteine amide decreases oxidative stress but not cell death induced by doxorubicin in H9c2 cardiomyocytes. BMC Pharmacol (2009) 0.92
Cardiotoxicity in childhood cancer survivors: strategies for prevention and management. Future Cardiol (2012) 0.91
Iron chelators with topoisomerase-inhibitory activity and their anticancer applications. Antioxid Redox Signal (2012) 0.91
Detection and monitoring of cardiotoxicity-what does modern cardiology offer? Support Care Cancer (2008) 0.91
Doxorubicin-induced carbonylation and degradation of cardiac myosin binding protein C promote cardiotoxicity. Proc Natl Acad Sci U S A (2014) 0.91
Recommendations for genetic testing to reduce the incidence of anthracycline-induced cardiotoxicity. Br J Clin Pharmacol (2016) 0.91
Dexrazoxane ameliorates doxorubicin-induced injury in mouse ovarian cells. Biol Reprod (2012) 0.89
The sulfhydryl containing compounds WR-2721 and glutathione as radio- and chemoprotective agents. A review, indications for use and prospects. Br J Cancer (1999) 0.89
Cardiac side effects of anticancer treatments: new mechanistic insights. Curr Heart Fail Rep (2012) 0.86
Systems biology approaches to adverse drug effects: the example of cardio-oncology. Nat Rev Clin Oncol (2015) 0.85
Cardiomyopathies: Evolution of pathogenesis concepts and potential for new therapies. World J Cardiol (2014) 0.85
The role of antioxidants in the era of cardio‑oncology. Cancer Chemother Pharmacol (2013) 0.84
Caspase-dependent and -independent suppression of apoptosis by monoHER in Doxorubicin treated cells. Br J Cancer (2007) 0.83
Acetaminophen attenuates doxorubicin-induced cardiac fibrosis via osteopontin and GATA4 regulation: reduction of oxidant levels. J Cell Physiol (2013) 0.82
Developing drugs to decrease the toxicity of chemotherapy. J Clin Oncol (2001) 0.82
Enhanced Cardiac Testing in a Dual Anti-HER2 Regimen: What Have We Learned? Oncologist (2016) 0.82
Visnagin protects against doxorubicin-induced cardiomyopathy through modulation of mitochondrial malate dehydrogenase. Sci Transl Med (2014) 0.81
Cardiovascular toxicities from systemic breast cancer therapy. Front Oncol (2014) 0.81
Prognostic role of troponin and natriuretic peptides as biomarkers for deterioration of left ventricular ejection fraction after chemotherapy. Arch Med Sci (2013) 0.81
A phase I study of oxaliplatin and doxorubicin in pediatric patients with relapsed or refractory extracranial non-hematopoietic solid tumors. Pediatr Blood Cancer (2013) 0.80
Use of biomarkers for the assessment of chemotherapy-induced cardiac toxicity. Clin Biochem (2014) 0.80
Prevention of Doxorubicin cardiopathic changes by a benzyl styryl sulfone in mice. Genes Cancer (2011) 0.79
Effects of MnDPDP and ICRF-187 on Doxorubicin-Induced Cardiotoxicity and Anticancer Activity. Transl Oncol (2012) 0.78
Dexrazoxane may prevent doxorubicin-induced DNA damage via depleting both topoisomerase II isoforms. BMC Cancer (2014) 0.78
Dexrazoxane Diminishes Doxorubicin-Induced Acute Ovarian Damage and Preserves Ovarian Function and Fecundity in Mice. PLoS One (2015) 0.78
The catalytic topoisomerase II inhibitor dexrazoxane induces DNA breaks, ATF3 and the DNA damage response in cancer cells. Br J Pharmacol (2015) 0.77
Dexrazoxane as a cardioprotectant in children receiving anthracyclines. Oncologist (2010) 0.77
Current views on anthracycline cardiotoxicity. Heart Fail Rev (2016) 0.77
Chemotherapy-induced cardiomyopathy. Heart Fail Rev (2015) 0.76
Dexrazoxane for the treatment of chemotherapy-related side effects. Cancer Manag Res (2014) 0.76
Efficacy and safety of Dexrazoxane (DRZ) in sarcoma patients receiving high cumulative doses of anthracycline therapy - a retrospective study including 32 patients. BMC Cancer (2016) 0.76
Angiotensin Converting Enzyme Inhibitors (ACEI) and doxorubicin pharmacokinetics in women receiving adjuvant breast cancer treatment. Springerplus (2015) 0.76
Preventing the cardiotoxicity of anthracyclines by dexrazoxane. BMJ (1999) 0.76
A rare case of the upper extremity diffuse large B-cell lymphoma mimicking soft tissue sarcoma in an elderly patient. Stem Cell Investig (2016) 0.76
Editorial: Antidotes and rescue therapies. Curr Pharm Biotechnol (2012) 0.75
Anthracycline-induced cardiomyopathy in a dog treated with epirubicin. Can Vet J (2015) 0.75
Cardioprotective Effect of Dexrazoxane in Patients with HER2-Positive Breast Cancer Who Receive Anthracycline Based Adjuvant Chemotherapy Followed by Trastuzumab. J Breast Cancer (2017) 0.75
Pregnancy in a patient with cancer and heart failure: challenges and complexities. J Adv Pract Oncol (2012) 0.75
Mechanisms of Cardiotoxicity of Cancer Chemotherapeutic Agents: Cardiomyopathy and Beyond. Can J Cardiol (2016) 0.75
Doxorubicin induced heart failure: Phenotype and molecular mechanisms. Int J Cardiol Heart Vasc (2016) 0.75
Potential Therapeutic Strategies for Hypertension-Exacerbated Cardiotoxicity of Anticancer Drugs. Oxid Med Cell Longev (2016) 0.75
Creating a Biomarker Panel for Early Detection of Chemotherapy Related Cardiac Dysfunction in Breast Cancer Patients. J Clin Exp Cardiolog (2017) 0.75
Global burden of cardiovascular diseases: part I: general considerations, the epidemiologic transition, risk factors, and impact of urbanization. Circulation (2001) 14.70
Survival and safety of exemestane versus tamoxifen after 2-3 years' tamoxifen treatment (Intergroup Exemestane Study): a randomised controlled trial. Lancet (2007) 8.08
The accuracy of Medicare's hospital claims data: progress has been made, but problems remain. Am J Public Health (1992) 6.97
Global burden of cardiovascular diseases: Part II: variations in cardiovascular disease by specific ethnic groups and geographic regions and prevention strategies. Circulation (2001) 6.29
Fluorescent speckle microscopy, a method to visualize the dynamics of protein assemblies in living cells. Curr Biol (1998) 5.69
Kirsten ras mutations in patients with colorectal cancer: the 'RASCAL II' study. Br J Cancer (2001) 5.36
XKCM1: a Xenopus kinesin-related protein that regulates microtubule dynamics during mitotic spindle assembly. Cell (1996) 5.21
Functional analysis of kinetochore assembly in Caenorhabditis elegans. J Cell Biol (2001) 4.82
Non-Hodgkin's lymphomas. IV. Clinicopathologic correlation in 405 cases. Cancer (1973) 4.66
Outbreak of aplastic crises in sickle cell anaemia associated with parvovirus-like agent. Lancet (1981) 4.62
Experimental parvoviral infection in humans. J Infect Dis (1985) 4.62
Analysis of human chromosome 21: correlation of physical and cytogenetic maps; gene and CpG island distributions. EMBO J (1990) 4.49
Parvovirus infections and hypoplastic crisis in sickle-cell anaemia. Lancet (1981) 4.44
Human parvovirus, the cause of erythema infectiosum (fifth disease)? Lancet (1983) 4.41
General practitioner obstetrics in Bradford. BMJ (1990) 4.28
Condoms prevent transmission of AIDS-associated retrovirus. JAMA (1986) 3.78
Cancer: improving early detection and prevention. A community practice randomised trial. BMJ (1992) 3.76
The spindle: a dynamic assembly of microtubules and motors. Nat Cell Biol (2001) 3.74
Obesity in C57BL/6J mice is characterized by adipose tissue hypoxia and cytotoxic T-cell infiltration. Int J Obes (Lond) (2007) 3.72
Multicenter phase II study of capecitabine in paclitaxel-refractory metastatic breast cancer. J Clin Oncol (1999) 3.62
Mortality associated with irinotecan plus bolus fluorouracil/leucovorin: summary findings of an independent panel. J Clin Oncol (2001) 3.21
Implication of a novel multiprotein Dam1p complex in outer kinetochore function. J Cell Biol (2001) 2.98
Arthropod-borne viral infections of man in Nigeria, 1964-1970. Ann Trop Med Parasitol (1975) 2.98
Physical fitness as a predictor of cardiovascular mortality in asymptomatic North American men. The Lipid Research Clinics Mortality Follow-up Study. N Engl J Med (1988) 2.84
Reconstitution of physiological microtubule dynamics using purified components. Science (2001) 2.83
Exemestane is superior to megestrol acetate after tamoxifen failure in postmenopausal women with advanced breast cancer: results of a phase III randomized double-blind trial. The Exemestane Study Group. J Clin Oncol (2000) 2.73
Chung-Strauss syndrome. J Assoc Physicians India (1993) 2.65
RNA CUG repeats sequester CUGBP1 and alter protein levels and activity of CUGBP1. J Biol Chem (2000) 2.65
Genetic map of diploid wheat, Triticum monococcum L., and its comparison with maps of Hordeum vulgare L. Genetics (1996) 2.59
Dissociable aspects of performance on the 5-choice serial reaction time task following lesions of the dorsal anterior cingulate, infralimbic and orbitofrontal cortex in the rat: differential effects on selectivity, impulsivity and compulsivity. Behav Brain Res (2003) 2.50
Blinded, randomized, multicenter study to evaluate single administration pegfilgrastim once per cycle versus daily filgrastim as an adjunct to chemotherapy in patients with high-risk stage II or stage III/IV breast cancer. J Clin Oncol (2002) 2.46
Within month variability in use of soup kitchens in New York State. p4. Am J Public Health (1988) 2.43
Body mass index, waist circumference and waist:hip ratio as predictors of cardiovascular risk--a review of the literature. Eur J Clin Nutr (2009) 2.35
Hip fracture incidence and mortality in New England. Epidemiology (1991) 2.32
Ethnic comparisons of the cross-sectional relationships between measures of body size with diabetes and hypertension. Obes Rev (2008) 2.32
Delayed administration of dexrazoxane provides cardioprotection for patients with advanced breast cancer treated with doxorubicin-containing therapy. J Clin Oncol (1997) 2.25
Glucose-6-phosphate dehydrogenase deficient red cells: resistance to infection by malarial parasites. Science (1969) 2.21
Roles of polymerization dynamics, opposed motors, and a tensile element in governing the length of Xenopus extract meiotic spindles. Mol Biol Cell (2005) 2.20
Rifampicin inhibition of ribonucleic acid and protein synthesis in normal and ethylenediaminetetraacetic acid-treated Escherichia coli. J Bacteriol (1970) 2.19
Science and government. Navigating the anthropocene: improving Earth system governance. Science (2012) 2.19
Reduction of cisplatin-induced emesis by a selective neurokinin-1-receptor antagonist. L-754,030 Antiemetic Trials Group. N Engl J Med (1999) 2.18
Esperanto for histones: CENP-A, not CenH3, is the centromeric histone H3 variant. Chromosome Res (2013) 2.12
A phase I/II trial of recombinant methionyl human brain derived neurotrophic factor administered by intrathecal infusion to patients with amyotrophic lateral sclerosis. Amyotroph Lateral Scler Other Motor Neuron Disord (2000) 2.12
Increased sickling of parasitised erythrocytes as mechanism of resistance against malaria in the sickle-cell trait. Lancet (1970) 2.11
The development and use of an antibody capture radioimmunoassay for specific IgM to a human parvovirus-like agent. J Hyg (Lond) (1982) 2.09
Diet in the epidemiology of cancer of the colon and rectum. J Natl Cancer Inst (1978) 2.05
Drugs as etiologic factors in the Stevens-Johnson syndrome. Am J Med (1968) 1.98
Third consensus on medical treatment of metastatic breast cancer. Ann Oncol (2009) 1.96
Infection with parvovirus-like virus and aplastic crisis in chronic hemolytic anemia. Ann Intern Med (1983) 1.89
Immunity, transferrin, and survival in kwashiorkor. Br Med J (1970) 1.89
A study of hospital staff attitudes concerning the comparative merits of antibiotics. Clin Pharmacol Ther (1971) 1.88
Profile of neurologic disorders associated with HIV/AIDS from Bangalore, south India (1989-96). Indian J Med Res (2000) 1.87
Hydroxyldaunomycin (Adriamycin) combination chemotherapy in malignant lymphoma. Cancer (1976) 1.85
A foodborne outbreak of gastroenteritis associated with Norwalk-like viruses: first molecular traceback to deli sandwiches contaminated during preparation. J Infect Dis (2000) 1.81
An overview of the CERC ARTEMIS project. Proc Annu Symp Comput Appl Med Care (1995) 1.80
Dengue viruses from febrile patients in Nigeria, 1964-68. Lancet (1971) 1.79
An erythema infectiosum-like illness caused by human parvovirus infection. N Engl J Med (1985) 1.77
A prospective randomized trial of 5-fluorouracil versus 5-fluorouracil and high-dose leucovorin versus 5-fluorouracil and methotrexate in previously untreated patients with advanced colorectal carcinoma. J Clin Oncol (1987) 1.75
HDL and the inflammatory response induced by LDL-derived oxidized phospholipids. Arterioscler Thromb Vasc Biol (2001) 1.74
High basal level gene expression of thymidine phosphorylase (platelet-derived endothelial cell growth factor) in colorectal tumors is associated with nonresponse to 5-fluorouracil. Clin Cancer Res (1998) 1.68
A single-blind comparison of intravenous ondansetron, a selective serotonin antagonist, with intravenous metoclopramide in the prevention of nausea and vomiting associated with high-dose cisplatin chemotherapy. J Clin Oncol (1991) 1.67
High resolution multimode digital imaging system for mitosis studies in vivo and in vitro. Biol Bull (1994) 1.66
Altered phosphorylation and intracellular distribution of a (CUG)n triplet repeat RNA-binding protein in patients with myotonic dystrophy and in myotonin protein kinase knockout mice. Proc Natl Acad Sci U S A (1997) 1.66
Endocrine treatment options for advanced breast cancer--the role of fulvestrant. Eur J Cancer (2005) 1.65
The cellular src gene product regulates junctional cell-to-cell communication. Science (1988) 1.65
Scar formation after stereotactic vacuum-assisted core biopsy of benign breast lesions. Clin Radiol (2006) 1.60
Enhanced anti-HIV functional activity associated with Gag-specific CD8 T-cell responses. J Virol (2010) 1.60
Evaluation of neoadjuvant chemotherapeutic response of locally advanced breast cancer by magnetic resonance imaging. Cancer (1996) 1.59
Diabetes mellitus in Nigerians: a study of 832 patients. West Afr Med J Niger Pract (1971) 1.59
Low-level c-myc amplification in human colonic carcinoma cell lines and tumors: a frequent, p53-independent mutation associated with improved outcome in a randomized multi-institutional trial. Cancer Res (1997) 1.58
A common progenitor for human myeloid and lymphoid cells. Nature (1978) 1.58
Superiority of nabilone over prochlorperazine as an antiemetic in patients receiving cancer chemotherapy. N Engl J Med (1979) 1.57
Diagnosis of human parvovirus infection by dot-blot hybridization using cloned viral DNA. J Med Virol (1985) 1.55
Biochemical assessment of protein-calorie malnutrition. Lancet (1969) 1.55
Characterization of the genome of the agent of erythrocyte aplasia permits its classification as a human parvovirus. J Gen Virol (1983) 1.53
Efficacy of oral ondansetron, a selective antagonist of 5-HT3 receptors, in the treatment of nausea and vomiting associated with cyclophosphamide-based chemotherapies. Ondansetron Study Group. Am J Clin Oncol (1994) 1.53
Localization of the sites of conduction abnormalities in a mouse model of myotonic dystrophy. J Cardiovasc Electrophysiol (1999) 1.53
The treatment of desmoid tumors: a stepwise clinical approach. Ann Oncol (2012) 1.53
A strategy for the development of secure telemedicine applications. Proc AMIA Annu Fall Symp (1997) 1.52
MR of parenchymal spinal cord signal change as a sign of active advancement in clinically progressive posttraumatic syringomyelia. AJNR Am J Neuroradiol (1998) 1.51
Glucose-6-phosphate-dehydrogenase deficiency, sickling, and malaria in African children in South Western Nigeria. Lancet (1967) 1.50
Efficacy of oral ondansetron in the prevention of emesis in outpatients receiving cyclophosphamide-based chemotherapy. The Ondansetron Study Group. Ann Intern Med (1993) 1.50
Induction of DNA strand breaks associated with apoptosis during treatment of leukemias. Leukemia (1993) 1.50
Proton MR spectroscopic measurement of neurometabolites in hepatic encephalopathy during oral lactulose therapy. AJNR Am J Neuroradiol (1998) 1.50
Metastases in small lymph nodes from colon cancer. Arch Surg (1987) 1.49
Non-Hodgkin's lymphomas. I. Bone marrow involvement. Cancer (1972) 1.49
Is cardiotoxicity being adequately assessed in current trials of cytotoxic and targeted agents in breast cancer? Ann Oncol (2010) 1.48
Genetic susceptibility to ozone-induced lung hyperpermeability: role of toll-like receptor 4. Am J Respir Cell Mol Biol (2000) 1.48